
100% French Stocks – 11/04/2025
100% French Stocks – 11/04/2025
CAC 40 PREOPEN: 8,023 points (-1.00%)
Key Stocks of the Day
Stellantis (STLA): Termination of its battery materials purchase agreement with Novonix. Potential impact on decarbonization strategy.
Edenred (EDEN): Presentation of a new 2025-2028 strategic plan with ambitious organic growth targets.
Biomérieux (BIM): Reduced its growth target, caution from investors expected.
Ayvens (ALD): Share placement completed, dilution risk to watch.
Beneteau (BEN): Aims to return to profitability in the second half. Orders bounced back in Q3 (+33%).
Coface (COFA): Reports a 9-month profit decline, impacted by a heightened risk environment.
Vicat (VCT): Confirms its 2025 revenue and EBITDA outlook.
Argan (ARG): Delivered a new 9,000 m² warehouse near Lens.
Vente-Unique (ALVU): Expanding into the Scandinavian market, a new milestone in its growth strategy.
Hydrogen Refueling Solutions (ALHRS): Opened a subsidiary in Dubai as part of international expansion.
Abivax (ABVX): Positive Phase III data for Obefazimod in ulcerative colitis.
NamR (ALNMR): Postponed publication of its half-year accounts.
Eurasia Group: Delayed publication of its results.
Vergnet (ALVER): Share consolidation at a ratio of 7,600 to 1 to remain listed, amid restructuring.
Omer-Decugis & Cie: EBITDA margin expected around 4.2%.
Keyrus (KEY): Sold its Digital Agency Datasolution business.
Forsee Power (FORSE): Appointed Philippe Platon as CFO.
Median Technologies (ALMDT): Strengthened its Board of Directors.
Cerinnov (ALCEN): Actively seeking a buyer.
Expected corporate results today
- Biomérieux (BIM): Q3 2025 publication at 07:00
- Rubis (RUI): Q3 2025 Trading Update after market close
- Beneteau (BEN): Q4 2024 results (estimate)
- Oeneo (SAON): Q2 2026 revenue (estimate)
- Transgene (TNG): Q3 2025 results at 17:45
- Maat Pharma (MAAT): Q3 2025 activity
- HiPay Group (HIPAY): Q3 2025 activity (pre-market)
- Broadpeak (ALBPK): Q3 2025 activity (after close)
- Biophytis (ALBPS): Q2 2025 results (estimate)
- Spineway (ALSPW): Q2 2025 results (estimate)
Analyst recommendations (French companies only)
Changes in recommendations
Upgraded
Airbus (AIR) → Morgan Stanley keeps "Overweight", price target raised from €231 to €250.
Nexans (NEX) → AlphaValue/Baader Europe maintains "Accumulate", price target raised from €145 to €149.
Neutral
Hermès (RMS) → Barclays lowers from "Overweight" to "Market weight", target reduced from €2,510 to €2,310.
Kering (KER) → Barclays maintains "Underweight", but raises target from €200 to €245.
Crédit Agricole (ACA) → JP Morgan maintains "Underweight", target reduced from €17 to €16.50.
Scor (SCR) → Jefferies retains, target reduced from €30 to €27.50. Morgan Stanley keeps "Overweight", target lowered from €34 to €33.
TotalEnergies (TTE) → Freedom Broker maintains "Buy", target lowered from $75 to $73.
Have a great session, everyone!
Sylvain Mouilhaud: Stocks coach.